pepscience

Bioregulator research · RESEARCH PROFILE

Vesugen (Lys-Glu-Asp)

A tripeptide explored in vascular and cellular regulation models.

1 specification·15 source documents·Source updated Jul 13, 2026

At a glance

A tripeptide explored in vascular and cellular regulation models.

This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.

How it works

Vesugen is associated with the Lys-Glu-Asp sequence. Proposed mechanisms include changes in endothelial-cell activity and gene-expression markers.[1][2][3]

Potential benefits & side effects

Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.

Potential benefits & research findings

The source discusses vascular and related experimental outcomes. Changes in cell markers do not establish improved circulation or a clinical vascular treatment.[2][3][5]

Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.

Side effects & evidence limitations

Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Vesugen (Lys-Glu-Asp).

Source-reported adverse effects and cautions

  • Generally well tolerated in reported studies; occasional mild injection-site reactions (redness/itch) may occur with subcutaneous administration.

    • Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.

    Editorial responsibility
    Pep Science editorial desk
    Last independent review
    Not yet recorded
    Editorial standards & corrections

    SPECIFICATIONS & SOURCE SCHEDULES

    Explore a vial size

    Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.

    Showing 20 mg · 1 source tables

    Source-derived research information. Table phases retain the source’s actual duration; open-ended phases are not converted into a fixed eight-week course. Review the original study before interpreting a schedule.

    Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

    Week 1Week 2Week 3Weeks 4–8+
    WeekDaily Dose (mcg)Units (per injection) (mL)
    Week 1500 mcg (0.5 mg)7.5 units (0.075 mL)
    Week 21000 mcg (1.0 mg)15 units (0.15 mL)
    Week 31500 mcg (1.5 mg)22.5 units (0.225 mL)
    Weeks 4–8+1500–2000 mcg (1.5–2.0 mg)22.5–30 units (0.225–0.30 mL)

    Frequency: Inject once daily subcutaneously. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Note that Week 1 dosing falls at 7.5 units; a 50-unit syringe with 0.5-unit graduations improves accuracy.

    Additional schedule context & duration

    Concise summary of the once-daily regimen.

    • Goal: Support vascular endothelial function and cellular renewal over time[2].
    • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
    • Dose Range: 500–2000 mcg daily with gradual titration.
    • Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
    • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

    Suggested daily titration approach.

    • Start: 500 mcg daily; increase by ~500 mcg weekly as tolerated.
    • Target: 1500–2000 mcg daily by Weeks 3–8+.
    • Frequency: Once per day (subcutaneous).
    • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
    • Timing: Any consistent time; rotate injection sites.

    Read this source protocol ↗ · View cited documents ↓

    Preparation

    Preparation and stability depend on the formulation, diluent, container and handling. The source-specific notes below apply to the selected record.
    Reconstitution Steps
    1. Draw 3.0 mL bacteriostatic water with a sterile syringe[7].
    2. Inject slowly down the vial wall; avoid foaming.
    3. Gently swirl/roll until dissolved (do not shake).
    4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light[8].

    Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

    Storage Instructions

    Proper storage preserves peptide quality[8].

    • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
    • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
    • Allow vials to reach room temperature before opening to reduce condensation uptake.

    Injection Technique

    General subcutaneous guidance from clinical best-practice resources[9].

    • Clean the vial stopper and skin with alcohol; allow to dry.
    • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[9][10].
    • Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
    • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[10].

    Understanding reconstitution ↗Storage principles ↗

    Materials & quantity planning

    Source materials checklist · 20 mg

    Plan based on an 8–16 week daily protocol with gradual titration (targeting ~1500 mcg/day maintenance).

    • Peptide Vials (Vesugen, 20 mg each):

      • 8 weeks (~84 mg total) ≈ 5 vials
      • 12 weeks (~126 mg total) ≈ 7 vials
      • 16 weeks (~168 mg total) ≈ 9 vials
    • Insulin Syringes (U-100):

      • Per week: 7 syringes (1/day)
      • 8 weeks: 56 syringes
      • 12 weeks: 84 syringes
      • 16 weeks: 112 syringes
    • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

      • 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
      • 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
      • 16 weeks (9 vials): 27 mL → 3 × 10 mL bottles
    • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

      • Per week: 14 swabs (2/day)
      • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
      • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
      • 16 weeks: 224 swabs → recommend 3 × 100-count boxes


    Calculate a phased quantity

    Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.

    Complete each phase to calculate totals.

    Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.

    FOLLOW THE EVIDENCE

    References & further reading

    Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.

    1. 01

      Research publication

      Bull Exp Biol Med (2016) — Short Peptides Regulate Gene Expression (Khavinson et al.) (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    2. 02

      Research publication

      Adv Gerontol (2014) — Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    3. 03

      Research publication

      Molecules (2021) — Peptide Regulation of Gene Expression: A Systematic Review (MDPI) (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    4. 04

      Research publication

      Adv Gerontol (2016) — Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    5. 05

      Research publication

      Bull Exp Biol Med (2021) — Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    6. 06

      Research publication

      Bull Exp Biol Med (2017) — Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer’s Disease (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    7. 07

      Public health resource

      DailyMed — Bacteriostatic Water injection, solution (FDA labeling) (opens in a new tab)

      dailymed.nlm.nih.gov

      Back to overview ↑
    8. 08

      Research publication

      PMC (2024) — Practical advice in the development of a lyophilized protein drug product (opens in a new tab)

      pmc.ncbi.nlm.nih.gov

      Back to overview ↑
    9. 09

      Public health resource

      MedlinePlus — Subcutaneous (SQ) injections: technique and site guidance (opens in a new tab)

      medlineplus.gov

      Back to overview ↑
    10. 10

      Public health resource

      NCBI Bookshelf — Best practices for injection (WHO guidelines) (opens in a new tab)

      www.ncbi.nlm.nih.gov

      Back to overview ↑
    11. 11

      Research publication

      Int J Mol Sci (2022) — Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    12. 12

      Research publication

      Pharmaceuticals (2021) — Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    13. 13

      Public health resource

      CDC — Vaccine administration: subcutaneous injection technique (opens in a new tab)

      www.cdc.gov

      Back to overview ↑
    14. 14

      Research publication

      Biogerontology (2010) — Peptide bioregulation of aging: Results and prospects (Anisimov & Khavinson) (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑
    15. 15

      Research publication

      Stem Cell Rev Rep (2020) — Peptide Regulation of Cell Differentiation (opens in a new tab)

      pubmed.ncbi.nlm.nih.gov

      Back to overview ↑

    Continue exploring

    Cartalax ↗Chonluten ↗Cortagen ↗

    Related topics are not interchangeable compounds or formulations.